AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Chamberlain et al.						Docket No. PU4759USW		
Application No.	Filing Date	Examiner		Customer N	o.	Group Art Unit	Confirmation No.	_
10/506,447	9/1/04	V. Balasubramanian		23347	ĺ	1624	9987	
Invention: DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITOR								_
		COMMISSIONER F	OR PATI	ENTS:				
Transmitted herew	ith is an amendment i	n the above-identified	application	on.				
The fee has been o	calculated and is trans	mitted as shown below	W .				···.	
		CLAIMS AS A	MENDE)				
	CLAIMS REMAINING	HIGHEST #	NUMB	ER EXTRA		RATE	ADDITIONAL	
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS	PRESENT			FEE	_
TOTAL CLAIMS	33 -	56 =			Х	\$50.00	\$0.00	_
INDEP. CLAIMS	2 -	3 =		0	X	\$200.00	\$0.00	_
Multiple Dependent Claims (check if applicable)							\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00 No additional fee is required for amendment.								=
 □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. □ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 □ Any additional filing fees required under 37 C.F.R. 1.16. □ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. 								
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
John L. Lemanow	Signature icz, Reg. No. 37,380	S	Dated	: // Ap	R I	1L 2007		
GlaxoSmithKline Five Moore Drive, PO Box 13398				I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date)				
cc:						Person Mailing Corro me of Person Mailin		_